Q2 Earnings Forecast for RYTM Issued By HC Wainwright

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Investment analysts at HC Wainwright issued their Q2 2026 earnings per share estimates for shares of Rhythm Pharmaceuticals in a research note issued on Monday, March 24th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of ($0.40) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.18) EPS.

Other equities research analysts also recently issued research reports about the stock. Canaccord Genuity Group boosted their target price on shares of Rhythm Pharmaceuticals from $80.00 to $81.00 and gave the company a “buy” rating in a research note on Thursday, February 27th. Jefferies Financial Group started coverage on Rhythm Pharmaceuticals in a research report on Thursday, January 2nd. They set a “buy” rating and a $80.00 target price for the company. The Goldman Sachs Group raised their price objective on shares of Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the company a “buy” rating in a research note on Thursday, December 5th. Oppenheimer assumed coverage on shares of Rhythm Pharmaceuticals in a report on Friday, December 20th. They set an “outperform” rating and a $76.00 price objective for the company. Finally, Morgan Stanley reissued an “overweight” rating and issued a $72.00 target price on shares of Rhythm Pharmaceuticals in a research note on Friday, March 7th. One analyst has rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $69.46.

Rhythm Pharmaceuticals Trading Down 1.5 %

Shares of NASDAQ RYTM opened at $52.91 on Tuesday. The business has a fifty day simple moving average of $55.28 and a 200 day simple moving average of $54.99. The firm has a market capitalization of $3.35 billion, a price-to-earnings ratio of -12.22 and a beta of 2.30. Rhythm Pharmaceuticals has a one year low of $35.17 and a one year high of $68.58.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The firm had revenue of $41.83 million for the quarter, compared to the consensus estimate of $38.48 million.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Castleark Management LLC raised its position in shares of Rhythm Pharmaceuticals by 1.3% in the third quarter. Castleark Management LLC now owns 19,260 shares of the company’s stock valued at $1,009,000 after purchasing an additional 250 shares during the period. Two Sigma Advisers LP raised its holdings in Rhythm Pharmaceuticals by 2.3% in the 4th quarter. Two Sigma Advisers LP now owns 13,100 shares of the company’s stock valued at $733,000 after acquiring an additional 300 shares during the period. SRS Capital Advisors Inc. increased its stake in shares of Rhythm Pharmaceuticals by 740.7% during the fourth quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock worth $25,000 after purchasing an additional 400 shares during the period. Raleigh Capital Management Inc. acquired a new position in Rhythm Pharmaceuticals in the 4th quarter valued at $28,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Rhythm Pharmaceuticals by 2.0% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,156 shares of the company’s stock worth $1,857,000 after buying an additional 654 shares during the period.

Insider Transactions at Rhythm Pharmaceuticals

In other news, CAO Christopher Paul German sold 635 shares of the business’s stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $57.22, for a total transaction of $36,334.70. Following the transaction, the chief accounting officer now directly owns 2,070 shares in the company, valued at $118,445.40. The trade was a 23.48 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Yann Mazabraud sold 75,000 shares of the firm’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the completion of the sale, the executive vice president now owns 40,370 shares of the company’s stock, valued at $2,078,247.60. This trade represents a 65.01 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 108,131 shares of company stock worth $5,781,098 in the last 90 days. Corporate insiders own 5.60% of the company’s stock.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.